travellinglight/iStock via Getty Images
Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial results of its Alzheimer’s drug candidate, simufilam.
The SEC’s charges relate